Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-octreotate versus 177Lu-octreotate + capecitabine in somatostatin receptor-positive GEP neuroendocrine tumors
NL-OMON25400Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of lutetium Lu 177 dotatate and capecitabine in Gastroenteropancreatic Carcinoid Tumor and Bronchopulmonary Carcinoid (BPC), sponsored by Erasmus MC. Primary endpoints: Objective tumor response, Overall survival and 1 more. Planned start Mar 2007; status: not yet recruiting.
02
Drugs
lutetium Lu 177 dotatatecapecitabine
03
Conditions
Gastroenteropancreatic Carcinoid TumorBronchopulmonary Carcinoid (BPC)
Beyond the preview
Go deeper on NL-OMON25400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25400.